Why the study?
The relationship between CYP2C19 polymorphisms and clopidogrel response in ischemic stroke patients remains controversial, with few data on secondary prevention.
Do CYP2C19 loss-of-function alleles increase the risk of recurrent stroke in patients treated for ischemic stroke?
Population
89 ischemic stroke patients without prior recurrence, sequelae, or bleeding diseases
Comparison
Carriers of CYP2C19 LOF alleles vs non-carriers
Design
Retrospective observational study
Authors
Loading...
CYP2C19 LOF alleles were associated with higher recurrent stroke risk; leaves open whether genotyping should guide therapy in IS secondary prevention.
Do CYP2C19 loss-of-function alleles increase the risk of recurrent stroke in patients treated for ischemic stroke?
CYP2C19 loss-of-function alleles are associated with a significantly increased risk of recurrent ischemic stroke, suggesting a potential need for alternative antiplatelet therapy in these patients.
Lin et al. (2021) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: